医学
内科学
危险系数
肿瘤科
肺癌
表皮生长因子受体
生物标志物
置信区间
免疫组织化学
队列
酪氨酸激酶抑制剂
前瞻性队列研究
癌症
生物化学
化学
作者
Kadoaki Ohashi,Kiichiro Ninomiya,Hiroshige Yoshioka,Akihiro Bessho,Takuo Shibayama,Keisuke Aoe,Nobuhisa Ishikawa,Toshiyuki Kozuki,Haruyuki Kawai,Shoichi Kuyama,Seigo Miyoshi,Kazunori Fujitaka,Hideto Obata,Yukari Tsubata,Yoshikazu Awaya,Masaaki Inoue,Koji Inoue,Naokatsu Horita,Hiroyuki Yanai,Katsuyuki Hotta
出处
期刊:Lung Cancer
[Elsevier BV]
日期:2020-10-01
卷期号:150: 83-89
被引量:11
标识
DOI:10.1016/j.lungcan.2020.09.024
摘要
Objectives Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small-cell lung carcinoma (NSCLC); however, a biomarker to predict their efficacy has not been established. Although human epidermal growth factor receptor-2 (HER2) aberrations constitute a potential mechanism for acquired resistance to EGFR-TKIs, the impact of HER2 on EGFR-TKI treatment outcomes has not been systematically evaluated. In this post-hoc subgroup study, we examined the impact of HER2 on the effect of EGFR-TKIs in patients with NSCLC harboring EGFR mutations. Materials and Methods Of 1126 patients with NSCLC enrolled into a prospective cohort study (HER2-CS study), we analyzed data of 356 (32 %) patients with EGFR-mutant tumors. HER2 protein expression levels were determined by immunohistochemistry (IHC) with the gastric cancer criteria. Patients were divided either to an HER2-P group (HER2-IHC2+/3+) or an HER2-N group (HER2-IHC0/1+). We primarily assessed differences in the time-to-treatment failure (TTF) of EGFR-TKI between the groups. Results The HER2 scoring was as follows: IHC0 (n = 76, 21 %), IHC1+ (n = 199, 56 %), IHC2+ (n = 72, 20 %), and IHC3+ (n = 9, 3 %). The patients’ demographics were similar in the HER2-P and HER2-N groups. The HER2-P group showed a significantly shorter EGFR-TKI TTF than the HER2-N group (hazard ratio [HR]: 1.657, 95 % confidence interval [CI]: 1.076–2.552; median: 13.3 vs. 19.1 months). The magnitude of the negative impact of TTF was especially dependent on performance status (PS). HER2 expression significantly deteriorated the TTF in the subgroup with PS 2 (HR: 5.497, 95 % CI: 1.510–20.02), but not in that with better PS (HR: 1.437, 95 % CI: 0.899–2.298) (pinteraction = 0.015). Conclusion In the current cohort, HER2 protein expression in EGFR-mutant NSCLC may have a negative impact on the effect of EGFR-TKIs, the effect of which was PS dependent.
科研通智能强力驱动
Strongly Powered by AbleSci AI